All Updates

All Updates

icon
Filter
Funding
LabGenius raises GBP 35 million in Series B funding to advance AI-powered drug discovery
AI Drug Discovery
May 21, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Yesterday
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Jun 17, 2024
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Jun 17, 2024
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Jun 17, 2024
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Jun 17, 2024
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Jun 17, 2024
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Jun 17, 2024
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Jun 17, 2024
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Jun 17, 2024
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Jun 17, 2024
AI Drug Discovery

AI Drug Discovery

May 21, 2024

LabGenius raises GBP 35 million in Series B funding to advance AI-powered drug discovery

Funding

  • AI-powered drug discovery startup LabGenius has secured GBP 35 million (USD 44.5 million) in a Series B funding round led by M Ventures. Existing investors Atomico and Kindred Capital and new investors Octopus Ventures and LG Corp also participated in the round.

  • The funds are planned to be used to broaden the scope of the company’s ML-powered discovery platform and advance its wholly-owned pipeline of multispecific antibodies to the clinical stage. Following the success of a recent research collaboration with Sanofi, the expanded platform is expected to enable broader strategic partnerships across various therapeutic areas.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.